Drug intelligence / Profile preview

HA115

Development stage: Discontinued
Lead developer: Conjupro Biotherapeutics
Modality: Small Molecules

Overview

HA115 is a small molecule drug that was initially developed by Conjupro Biotherapeutics. It was investigated for immune system diseases and respiratory diseases, with a particular focus on asthma. The drug reached Phase 1 clinical trials, where it was administered orally in capsule form to healthy adult volunteers in randomized, double-blind, placebo-controlled studies to assess safety and pharmacokinetics. However, development of HA115 has been discontinued and there are no active indications or ongoing trials reported[2][3].

Beyond the preview

Go deeper on HA115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HA115.

Explore the full profile